| Abbreviations |
|
2 | (2) |
|
Table 1 Clinical Approach to Initial Choice of Antimicrobial Therapy |
|
|
4 | (65) |
|
Table 2 Recommended Antimicrobial Agents Against Selected Bacteria |
|
|
69 | (3) |
|
Table 3 Suggested Duration of Antibiotic Therapy for Selected Clinical Syndromes in Immunocompetent Patients |
|
|
72 | (1) |
|
Table 4A Antibacterial Activity Spectra |
|
|
73 | (6) |
|
4B Antifungal Activity Spectra |
|
|
79 | (1) |
|
4C Antiviral Activity Spectra |
|
|
80 | (1) |
|
Table 5A Treatment Options For Systemic Infection Due To Multi-Drug Resistant Gram-Positive Bacteria |
|
|
81 | (1) |
|
5B Treatment Options for Systemic Infection Due to Selected Multi-Drug Resistant Gram-Negative Bacilli |
|
|
82 | (1) |
|
Table 6 Suggested Management of Suspected or Culture-Positive Community-Associated Methicillin-Resistant S. aureus Infections |
|
|
83 | (1) |
|
Table 7 Antibiotic Hypersensitivity Reactions & Drug Desensitization Methods |
|
|
84 | (2) |
|
Table 8 Pregnancy Risk and Safety in Lactation |
|
|
86 | (3) |
|
Table 9A Selected Pharmacologic Features of Antimicrobial Agents |
|
|
89 | (10) |
|
9B Pharmacodynamics of Antlbacterials |
|
|
99 | (1) |
|
9C Enzyme and Transporter - Mediated Interactions of Antimicrobials |
|
|
99 | (3) |
|
Table 10A Antibiotic Dosage and Side-Effects |
|
|
102 | (12) |
|
10B Selected Antibacterial Agents--Adverse Reactions--Overview |
|
|
114 | (2) |
|
10C Antimicrobial Agents Associated with Photosensitivity |
|
|
116 | (1) |
|
10D Aminoglycoside Once-Daily and Multiple Daily Dosing Regimens |
|
|
117 | (1) |
|
10E Prolonged or Continuous Infusion Dosing of Selected Antibiotics |
|
|
118 | (1) |
|
10F Inhalation Antibiotics |
|
|
119 | (1) |
|
Table 11A Treatment of Fungal Infections---Antimicrobial Agents of Choice |
|
|
120 | (12) |
|
11B Antifungal Drugs: Dosage, Adverse Effects, Comments |
|
|
132 | (3) |
|
Table 12A Treatment of Mycobacterial Infections |
|
|
135 | (11) |
|
12B Dosage and Adverse Effects of Antimycobacterial Drugs |
|
|
146 | (3) |
|
Table 13A Treatment of Parasitic Infections |
|
|
149 | (12) |
|
13B Dosage and Selected Adverse Effects of Antiparasitic Drugs |
|
|
161 | (3) |
|
13C Parasites that Cause Eosinophils (Eosinophilia In Travelers) |
|
|
164 | (1) |
|
13D Sources for Hard-to-Find Antiparasitic Drugs |
|
|
164 | (1) |
|
Table 14A Antiviral Therapy |
|
|
165 | (11) |
|
14B Antiviral Drugs (Non-HIV) |
|
|
176 | (5) |
|
14C Antiretroviral Therapy (ART) in Treatment-Naive Adults (HIV/AIDS) |
|
|
181 | (11) |
|
14D Antiretroviral Drugs and Adverse Effects |
|
|
192 | (4) |
|
14E Hepatitis A & HBV Treatment |
|
|
196 | (1) |
|
14F HCV Treatment Regimens and Response |
|
|
197 | (4) |
|
Table 15A Antimicrobial Prophylaxis for Selected Bacterial Infections |
|
|
201 | (2) |
|
15B Antibiotic Prophylaxis to Prevent Surgical Infections in Adults |
|
|
203 | (3) |
|
15C Antimicrobial Prophylaxis for the Prevention of Bacterial Endocarditis in Patients with Underlying Cardiac Conditions |
|
|
206 | (1) |
|
15D Management of Exposure to HIV-1 and Hepatitis B and C |
|
|
207 | (3) |
|
15E Prevention of Selected Opportunistic Infections in Human Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT) in Adults With Normal Renal Function |
|
|
210 | (2) |
|
Table 16 Pediatric dosing (Age >28 Days) |
|
|
212 | (4) |
|
Table 17A Dosages of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
216 | (15) |
|
17B No Dosage Adjustment with Renal Insufficiency by Category |
|
|
231 | (1) |
|
17C Antimicrobial Dosing in Obesity |
|
|
231 | (1) |
|
Table 18 Antimicrobials and Hepatic Disease: Dosage Adjustment |
|
|
232 | (1) |
|
Table 19 Treatment of CAPD Peritonitis in Adults |
|
|
233 | (1) |
|
Table 20A Anti-Tetanus Prophylaxis, Wound Classification, Immunization |
|
|
234 | (1) |
|
20B Rabies Postexposure Prophylaxis |
|
|
235 | (1) |
|
Table 21 Selected Directory of Resources |
|
|
236 | (1) |
|
Table 22A Anti-Infective Drug-Drug Interactions |
|
|
237 | (8) |
|
22B Drug-Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) and Protease Inhibitors |
|
|
245 | (1) |
|
Table 23 List of Generic and Common Trade Names |
|
|
246 | (2) |
| Index |
|
248 | |
